OPINION & ORDER
SIDNEY H. STEIN, District Judge.
This securities fraud action arises from a merger between Bioenvision, Inc. and Genzyme Corporation, two pharmaceutical companies. Plaintiffs—sellers of securities in Bioenvision during the period from April 11, 2007 through May 28, 2007 (the "class period")—bring this putative class action against Bioenvision and six of its corporate officers and directors (collectively, the "Bioenvision...
Let's get started

Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.
- Updated daily.
- Uncompromising quality.
- Complete, Accurate, Current.